<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719574</url>
  </required_header>
  <id_info>
    <org_study_id>2102-HEM-101</org_study_id>
    <nct_id>NCT02719574</nct_id>
  </id_info>
  <brief_title>Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation</brief_title>
  <official_title>A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forma Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forma Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single
      agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is
      split into 2 distinct parts: a dose escalation part, which will utilize an open-label design
      of FT-2102 (single agent) and FT-2102 + azacitidine (combination agent) administered via one
      or more intermittent dosing schedules followed by a dose expansion part. The dose expansion
      part will enroll patients in up to 5 expansion cohorts, exploring single-agent FT-2102
      activity as well as combination activity with azacitidine or cytarabine. Following the
      completion of Phase 1, Phase 2 will begin enrollment. Patients will be enrolled across 6
      different cohorts, examining the effect of FT-2102 (as a single agent) and FT-2102 +
      azacitidine (combination) on various AML/MDS disease states.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Doses (MTDs) or Maximum Evaluated Doses (MEDs) [Phase 1]</measure>
    <time_frame>Within first 4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with a Dose Limiting Toxicity (DLT) [Phase 1]</measure>
    <time_frame>Within first 4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Doses recommended for future studies [Phase 1]</measure>
    <time_frame>Within first 4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR, CRi, MLFS, Marrow CR) Rate of FT-2102 single-agent or in combination with Azacitidine in patients with AML/MDS [Phase 2]</measure>
    <time_frame>As per IWG Response Assessment Guidelines for AML and MDS based on investigator's assessment on day 1 of each cycle through study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak plasma concentration Tmax [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for half of the drug to be absent in blood stream following dose (T 1/2) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate at which drug is removed from blood stream (CL/F) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of drug distribution within the blood stream (Vd/F) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of antileukemic or antimyelodysplastic activity of FT-2102 as determined by CR, CRi, MLFS, Marrow CR, PR, and SD as a single-agent or in combination with azacitidine or cytarabine [Phase 1]</measure>
    <time_frame>As per IWG Response Assessment Guidelines for AML and MDS based on investigator's assessment on day 1 of each cycle through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events, clinical laboratory abnormalities, and changes in ECG parameters as assessed by CTCAE v4.0 as a single-agent or in combination with azacitidine [Phase 2]</measure>
    <time_frame>Safety will be assessed from time of first dose through 28 days post last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional measures of antileukemic or antimyelodysplastic activity as determined by CRh, Overall Response (OR), and Stable Disease of FT-2102 alone or in combination with azacitidine [Phase 2]</measure>
    <time_frame>As per IWG Response Assessment Guidelines for AML and MDS based on investigator's assessment on day 1 of each cycle through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) [Phase 2]</measure>
    <time_frame>From first dose of study drug through time of first response by blood recovery count, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) [Phase 2]</measure>
    <time_frame>From time of first response by blood recovery count through relapse, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) [Phase 2]</measure>
    <time_frame>From time of entry on study through progression, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) [Phase 2]</measure>
    <time_frame>From time of entry on study through death or date last known alive at end of follow-up, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>PH1 Dose Escalation &amp; Expansion FT-2102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH1 Esc. and Exp. FT-2102+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH1 Esc. and Exp. FT-2102+Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 1 FT-2102 Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the completion of Phase 1, Phase 2 Cohort 1 will commence enrollment wherein patients with relapsed or refractory (R/R) AML will be treated with the RP2D of FT-2102 as a single-agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 2 FT-2102 Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2 Cohort 2, patients with AML/ MDS in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after cytotoxic-containing induction therapy with residual IDH-R132 mutation will be treated at the RP2D of FT-2102 as a single-agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 3 FT-2102 Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2 Cohort 3, patients with R/R AML/MDS, previously treated with an IDH1 inhibitor will be treated at the RP2D of FT-2102 as a single-agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 4 FT-2102+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2 Cohort 4, patients with R/R AML/MDS that are na√Øve to prior hypomethylating therapy and IDH1 inhibitor therapy will be treated with the RP2D of FT-2102 in combination with azacitidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 5 FT-2102+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2 Cohort 5, patients with R/R AML/MDS that have inadequately responded or have progressed immediately proceeding hypomethylating therapy will be treated with the RP2D of FT-2102 in combination with azacitidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 6 FT-2102+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2 Cohort 6, patients with R/R AML/MDS that have been previously treated with single-agent IDH1 inhibitor therapy as their last therapy prior to study enrollment will be treated with the RP2D of FT-2102 in combination with azacitidine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT-2102</intervention_name>
    <description>FT-2102 will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level</description>
    <arm_group_label>PH1 Dose Escalation &amp; Expansion FT-2102</arm_group_label>
    <arm_group_label>PH1 Esc. and Exp. FT-2102+Azacitidine</arm_group_label>
    <arm_group_label>PH1 Esc. and Exp. FT-2102+Cytarabine</arm_group_label>
    <arm_group_label>PH2 Cohort 1 FT-2102 Single Agent</arm_group_label>
    <arm_group_label>PH2 Cohort 2 FT-2102 Single Agent</arm_group_label>
    <arm_group_label>PH2 Cohort 3 FT-2102 Single Agent</arm_group_label>
    <arm_group_label>PH2 Cohort 4 FT-2102+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 5 FT-2102+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 6 FT-2102+Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>azacitidine will be administered per site's standard of care</description>
    <arm_group_label>PH1 Esc. and Exp. FT-2102+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 4 FT-2102+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 5 FT-2102+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 6 FT-2102+Azacitidine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>cytarabine will be administered per site's standard of care</description>
    <arm_group_label>PH1 Esc. and Exp. FT-2102+Cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven acute myeloid leukemia (AML) or intermediate, high-risk, or very
             high risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization
             (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R) which is
             relapsed or refractory (R/R) to standard therapy and/or for which standard therapy is
             contraindicated or which has not adequately responded to standard therapy.

          -  Patients must have documented IDH1-R132 gene-mutated disease as evaluated by the site

          -  Good performance status

          -  Good kidney and liver function

        Exclusion Criteria:

          -  Patients with symptomatic central nervous system (CNS) metastases or other tumor
             location (such as spinal cord compression, other compressive mass, uncontrolled
             painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention,
             palliative care, surgery or radiation therapy

          -  Congestive heart failure (New York Heart Association Class III or IV) or unstable
             angina pectoris. Previous history of myocardial infarction within 1 year prior to
             study entry, uncontrolled hypertension or uncontrolled arrhythmias

          -  Pulmonary disease (e.g. COPD, asthma, etc) that is not controlled (moderate to severe
             symptoms) with current medication

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam</last_name>
      <phone>310-794-0242</phone>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linh Dang-Chu</last_name>
      <phone>916-734-5930</phone>
      <email>ldangchu@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Malak</last_name>
      <phone>203-785-4699</phone>
      <email>Tanya.Malak@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami, Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Englund</last_name>
      <phone>305-243-6899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <email>ClinicalTrials@FLCancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirra Dinner, MD</last_name>
      <phone>312-472-1234</phone>
      <email>Shira.Dinner@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Coleman</last_name>
      <email>melanie.Coleman@franciscanalliance.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine Greenebaum Comprehensive</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxia Li</last_name>
      <phone>410-328-8370</phone>
      <email>hongxiali@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Garn</last_name>
      <phone>313-576-9685</phone>
      <email>garnt@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>800-767-9355</phone>
      <email>askroswell@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Marx</last_name>
      <email>Dmarx@nycancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Baskind</last_name>
      <email>Paul_Baskind@nymc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Leach</last_name>
      <phone>212-304-5585</phone>
      <email>sl3971@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine/New York-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Lascu</last_name>
      <phone>212-746-0974</phone>
      <email>ell2028@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Clinical Trials Office</last_name>
      <phone>631-638-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Brenner</last_name>
      <email>Lisa.Brenner@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chase Brockett</last_name>
      <phone>503-346-0227</phone>
      <email>brocketc@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Walls</last_name>
      <email>sarah.walls@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebekah Taylor</last_name>
      <phone>615-936-1936</phone>
      <email>Rebekah.J.Taylor@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Cortes, MD</last_name>
      <phone>713-794-5783</phone>
      <email>jcortes@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Bailey</last_name>
      <phone>206-215-1471</phone>
      <email>Neil.Bailey@swedish.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wei, MD</last_name>
      <email>andrew.wei@monash.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>IDH1</keyword>
  <keyword>IDH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

